|
ImmuneRegen BioSciences to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference ImmuneRegen Scientist to Present Viprovex® Pre-Clinical Study Findings at 2008 BARDA Industry Day UNC Charlotte to Evaluate Potential Adjuvant Activity of ImmuneRegen's Viprovex® With Cancer Vaccine ASU's Biodesign Institute and ImmuneRegen Collaborate to Investigate Possible Enhancement of Vaccine Against Norwalk Viruses ImmuneRegen® BioSciences Confirms Homspera® Advances Wound Healing in Topical Application IR BioSciences Holdings, Inc. Closes New $5 Million Funding Round
|
Corporate OverviewIR BioSciences Holdings, Inc. is a development-stage biotechnology company. Through our wholly-owned subsidiary ImmuneRegen BioSciences, Inc., we are engaged in the research and development of potential drug candidates, Homspera™ and its derivatives, Radilex® and Viprovex®. Our goals include developing these potential drug candidates to be used as possible countermeasures for homeland security threats, including radiological, chemical and biological agents, and to meet the commercial need for similar beneficial effects in conditions such as radiation therapy, influenza, anthrax and potentially other microbial ailments. We have discovered activities of Homspera that may potentially open additional commercialization opportunities in areas such as human adult stem cell stimulation, vaccine adjuvants, which stimulate the immune system above that of a stand-alone vaccine, and wound healing.
|
News and Events - Click Here